T issue factor (TF) is the principal initiator of the clotting cascade and is considered to be a major regulator of hemostasis and thrombosis. 1, 2 Minimal TF activity is found in quiescent cultures of smooth muscle cells (SMCs), endothelial cells, fibroblasts, and macrophages. TF is induced by a variety of agonists, including growth factors and cytokines. [2] [3] [4] In animal models of arterial injury, TF is rapidly induced in the medium and accumulates in the neointimal SMCS. [5] [6] [7] [8] TF is also abundant in macrophages and SMCs of atherosclerotic plaques. 9 -14 TF consists of a short cytoplasmic tail, single transmembrane domain, and large extracellular domain. The extracellular domain binds factors VII and VIIa, and the resulting complex acts as a catalyst for the conversion of factors IX and X to IXa and Xa, respectively, triggering coagulation. 2, 15 To be active, TF must reside in the appropriate phospholipid environment, such as that provided by plasma membranes containing phosphatidylserine or phosphatidylethanolamine. It has been thought that TF is exclusively cell-associated and that physiologically relevant TF is induced on the cell surface.
Recent data suggest that active TF may be present extracellularly. In atherosclerotic plaques, TF antigen is detected in the extracellular matrix and is most abundant in the acellular lipid-rich core. 10, 14 TF antigen is also present in the extracellular space surrounding intimal SMCs of injured vessels. 14 We have recently found that the intimal TF activity accumulating after balloon injury of rat aortas can be washed off the surface under low shear conditions. 16 TF antigen and activity also have been detected in circulating blood. [17] [18] [19] [20] Although it has been assumed that the blood TF is located on leukocytes, particularly monocytes, active TF has been identified in the cell-free plasma, 19 where it seems to reside in small particles. The source and the mechanism by which extracellular TF is generated remain to be determined.
We now report that active TF is released into the medium of cultured arterial SMCs. This activity exists largely in microparticles (Յ200 nm). We hypothesize that the extracellular TF found in the injured arterial wall and atherosclerotic plaques derives in part from these SMC-derived particles.
Materials and Methods

Cell Culture
Human coronary arteries and aortic SMCs were prepared as previously described. 21 Wild-type human melanoma cells and cells overexpressing TF were provided by Dr Michael Bromberg (Yale University, New Haven, Conn) and grown as described. 22 
Plasmid Construction
The coding region of human TF cDNA (GenBank accession No. J0293) was ligated into the pEGFP-N3 vector (accession No. U57609). Construct TF:TM Ϫ contained only the extracellular domain of TF (bases 112 to 865). For TF:PI, the transmembrane and cytoplasmic domains (bases 865 to 996) were substituted with a sequence encoding the carboxy-terminal 37 amino acids of decayaccelerating factor, a phosphatidylinositol-anchored protein. 23 
Transient Transfection Assays
Cells were transfected with 10 g of TF constructs by CaCl 2 precipitation as described. 24 
Determination of TF Activity
Confluent SMCs were washed twice and incubated with fresh defined medium (DM). 21 At various times, 160-L aliquots of the medium were assayed for TF, as described. 21 Human recombinant factor VIIa was a gift from Novo Nordisk A/S, (Gentoffe, Denmark). Factor X was purified from human plasma. 25 Cellular TF was measured after lysis in 15 mmol/L octyl-␤-D-glycopyranoside (BOG), as described. 21 
Sucrose Gradient Centrifugation
Medium was harvested from cells, clarified at 2000g for 10 minutes, and spun at 265 000g for 1 hour onto a 1-mL sucrose cushion (60% wt/wt). A 1-mL fraction directly overlying the cushion (containing Ͼ95% of the total TF activity) was made 60% in sucrose and overlayered with sucrose gradients. The gradients were centrifuged for 80 hours at 265 000g. Fractions of 0.60 mL were collected and assayed for TF activity, density, and total protein by Bradford assay.
Western Blot Analysis
Medium from monolayers of SMCs (100 mL) or melanoma cells (30 mL) was clarified at 2000g and spun at 265 000g for 30 minutes. Then the pellet was washed once in 10 mmol/L HEPES (0.14 mol/L NaCl, pH 7.5) and resuspended in 50 L of gel-loading buffer containing 10% (wt/vol) ␤-mercaptoethanol. Western blotting was performed as described. 26 
Flow Cytometry
Mean fluorescent intensity was determined at 488 nm using an EPICS Profile II flow cytometer with Elite software (Coulter Electronics). Background cell autofluorescence was assessed by omitting the primary antibody. Particle size was determined by comparison with carboxylate-modified fluorescent microspheres (FluoSpheres, Molecular Probes).
Immunoprecipitation of TF Activity
The medium was concentrated on a 1-mL sucrose cushion, as described above. Aliquots of 100 L were incubated for 24 hours at room temperature with antibodies coupled to protein A sepharose beads. The mixture was centrifuged at 2000g, and the supernatants were assayed for TF activity. The beads were washed in PBS and incubated for 1 hour in 100 L of 15 mmol/L BOG before assay.
An expanded Materials and Methods section is available online at http://www.circresaha.org.
Results
Active TF Is Present in the Medium of SMCs and Melanoma Cells
Aortic SMCs were washed and incubated with fresh DM. 21 Minimal TF activity was detectable immediately after washing but subsequently accumulated in the medium ( Figure 1A ). Similar results were obtained with coronary artery SMCs (not shown). Phorbol 12-myristate 13-acetate (PMA), tumor ne- crosis factor-␣, and platelet-derived growth factor (PDGF), activators of TF synthesis, caused Ϸ3-fold increases in TF activity in the medium (Figure 2 ). Interleukin-1␣ (IL-1␣) alone or in combination with indomethacin, which potentiates the mitogenic activity of IL-1␣ in SMCs, 27 did not increase TF activity in the medium or cell lysates (not shown). At 24 hours, TF activity in the medium was Ϸ10% of that measured in lysates of the underlying cells whether incubated in DM or treated with agonists. Agonist-mediated increases in TF activity in the medium seem related to changes in TF synthesis rather than enhancement of TF release from SMCs. High levels of TF accumulated in the medium of melanoma cells overexpressing wild-type TF or TF lacking its cytoplasmic domain 22 ( Figure 1B ) and represented Ϸ15% of cellular TF activity.
Rat aortic SMCs and human melanoma cells were transiently transfected with full-length human TF cDNA, and TF activity was assayed in the medium at 24 hours (SMC, 1.5Ϯ0.21; melanoma, 0.8Ϯ0.15 fmol/mLϮSD; nϭ3 experiments). Cells transfected with TF lacking the transmembrane domain (TF:TM Ϫ ) displayed minimal TF activity in the medium (SMC, 0.2Ϯ0.03; melanoma, 0.1Ϯ0.04; PϽ0.001 compared with wild type). In contrast, cells transfected with TF containing an alternative transmembrane and cytoplasmic domain (TF:PI) had levels comparable to wild type (SMC, 0.8Ϯ0.3; melanoma, 0.6Ϯ0.08; nϭ3, Pϭnot significant compared with wild type). Thus, insertion into the plasma membrane seems critical for release of active TF.
Extracellular TF Is Not Inhibited by Tissue Factor Pathway Inhibitor or Encrypted
Tissue factor pathway inhibitor (TFPI) is a circulating inhibitor of TF 28 and has been shown to attenuate TF activity in atherosclerotic plaques. 29 Antibodies to TFPI had no effect on the levels of TF activity accumulating in DM ( Figure 3A) , suggesting that TF activity is not reduced by the presence of TFPI secreted by the underlying SMCs. Less TF activity was measured when cells were incubated in medium containing 10% FBS; after treatment with antibody to TFPI, levels were identical to those measured in DM. Thus, FBS does contain TFPI, which attenuates TF activity in the medium.
TF is present on the surface of many cells in a largely inactive, encrypted form. 21 Release of the cells from the culture dish or treatment with detergent deencrypts TF. To determine whether there is encrypted TF in the medium, activity was measured in the presence and absence of detergent. BOG did not increase TF activity in the medium but, rather, decreased it by Ϸ50% ( Figure 3B ). In contrast, BOG caused an Ϸ10-fold increase in TF activity in intact SMCs, consistent with deencryption. In the medium, TF may be oriented only on the outside of microparticles. Detergent could cause a rearrangement of TF molecules such that they would be dispersed randomly on both sides of the microparticles, leading to a 50% decrease in activity. Alternatively, BOG could directly affect the measurement of TF activity. As shown in the inset, BOG in the concentrations used for these experiments had no direct effect on TF activity measured using a TF standard inserted randomly in 30% phosphatidylserine and 70% phosphatidylcholine vesicles.
The medium was also treated with 35 mol/L (final concentration) of 20% phosphatidylserine and 80% phosphatidylcholine. 30 This relipidation protocol did not result in a significant increase in TF activity ( Figure 3C ), indicating that all of the released TF was associated with appropriate lipids.
Characterization of TF in the Culture Medium
Minimal TF activity (Ϸ10%) was removed from the medium by low-speed centrifugation (Յ20 000g). In contrast, virtually all of the activity (Ͼ95%) was precipitated at 100 000g. On Western blots (Figure 4) , the size of the TF in the medium was identical to the major band identified from human brain extracts (the higher molecular weight band represents TF dimers). A slightly smaller band was purified from the medium of melanoma cells expressing the cytoplasmic domain mutant, commensurate with its smaller size. This shows that TF in the medium is not derived from enzymatic cleavage of the extracellular domain.
Flow cytometry ( Figure 5 ) showed that the medium contained microparticles that migrated predominantly with a bead size Յ200 nm, as indicated by the log of forward scatter. As shown in the Table, Ϸ53% of these particles were positive for TF. Similarly, Ϸ59% of the underlying SMCs were positive for TF. TFPI was not detected on the cells or microparticles. Although ␣ v and ␤ 1 were expressed on the majority of SMCs, they were present on a much smaller fraction of microparticles. In addition, ␣ 5 was not detected on microparticles, although it was detectable on approximately one third of cells.
When the medium was spun at 245 000g, virtually all of the activity (Ͼ95%) was recovered in a 0.6-mL fraction overlying a 60% sucrose bed. This fraction was overlayered with a stepwise sucrose gradient and centrifuged for 80 hours at 245 000g. All of the TF activity ( Figure 6A ) was found at the top. TF-overexpressing melanoma cells yielded similar results (not shown). As determined using a continuous 40% to 20% sucrose gradient (Figure 6B ), the TF activity migrated with a density of Ϸ1.10 g/mL, consistent with its association with a lipid-containing particle.
To determine whether TF is associated with an LDL-like particle, the medium was treated with antibodies to apolipoprotein B under conditions shown previously to precipitate 
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LDL 31 ; this had no effect on TF activity (Figure 7 ). Precipitating antibodies to apolipoprotein A1, a major component of HDL also had no effect. Antibodies to TF removed Ϸ90% of TF activity from the medium. TF activity was not precipitated from the medium with antibodies to ␣ v or ␣ 5 . However, Ϸ33% of TF activity was removed from the medium with antibody to ␤ 1 . This activity was recovered quantitatively from the immunoprecipitate. Similar results were obtained from the medium of SMCs treated for 24 hours with PDGF. Precipitating antibodies to annexin V, commonly found on apoptotic vesicles, had no effect on the levels of TF activity.
Discussion
We previously reported that TF is present in SMCs in 3 distinct cellular pools. 21 The appearance of surface TF activity was transient, peaking 4 to 6 hours after growth factor stimulation. The majority (Ϸ80%) of the TF was present in an intracellular pool and encrypted on the cell surface. In the present study, active TF was found to accumulate in the culture medium, representing Ϸ10% of the activity measured from total cell extracts at 24 hours. The TF activity in the medium may represent a more stable source of SMC-derived procoagulant activity than that found on the cell surface. The centrifugation and fluorescent cytometric studies suggest that the majority of TF activity is in a small microparticle (Յ200 nm) with a very low density consistent with a high lipid content. It has recently been reported that apolipoprotein B-containing lipoproteins of various densities can be secreted by extrahepatic cells. 32 TFPI has also been shown to associate with LDL particles. 33, 34 However, TF could not be precipitated from the culture medium by antibodies to the apolipoprotein B moiety of LDL or the apolipoprotein A1 moiety of HDL.
Another potential source of TF activity in the medium is apoptotic vesicles, in which procoagulant activity has been found. 35, 36 In addition, TF-containing microparticles, thought to be derived from apoptotic macrophages and lymphocytes, have recently been identified in atherosclerotic plaques. 37 The SMCs used in these studies have very low levels of apoptosis (Ͻ1% after 24 hours of incubation in DM as determined by fluorescent cytometric analysis [A.D.S., M.R., M.B.T., unpublished observations, 2000]). In addition, TF activity in the medium could not be precipitated with antibodies to annexin V, a common component of apoptotic vesicles. 38 In response to trypsin and calcium ionophore, TFcontaining vesicles bud off the surface of fibroblasts and WISH amnion cells. 39, 40 TF has also been found in monocytederived microparticles in response to endotoxin. 41 Similarly, vesicles containing TF may bud off the surface of SMCs as a normal concomitant of cell activation. Such vesicles would also be expected to have a high lipid content. Flow cytometry showed that approximately half of the SMCs expressed surface TF. This is in keeping with our previous finding that although virtually all SMCs stain for TF antigen, expression of surface TF is transient. 21 Approximately half of the microparticles also had detectable TF antigen. Although the vast majority of SMCs expressed ␣ v -and ␤ 1 -containing integrins, a much smaller percentage of microparticles were positive for these antigens. These data support the concept that although TF-containing particles may be derived by budding from the cell surface, they seem to be enriched for TF relative to surface integrins.
Only antibody to ␤ 1 was capable of precipitating TF activity from the medium. Of note was that approximately one third of the microparticles expressed ␤ 1 by flow cytometry, and antibody to ␤ 1 precipitated approximately one third of the TF activity. This suggests that there is no selection for or against ␤ 1 in TF-containing microparticles. In contrast, although Ϸ20% of microparticles have detectable ␣ v by flow cytometry, antibody to ␣ v failed to precipitate TF activity, suggesting that this integrin may specifically be excluded from TF-containing microparticles or be present at concentrations too low to be precipitated. All antibodies to integrins were used at concentrations known to immunoprecipitate their respective antigens from cell lysates. 42 Figure 6 . Sucrose gradient centrifugation of TF. SMCs were incubated for 24 hours in 10% FBS. The medium was spun onto a 60% sucrose cushion and then overlayered with a discontinuous sucrose gradient (successive 1.2-mL volumes of 56%, 53%, 47%, 44%, 41%, 38%, 35%, and 28% sucrose) (A) or overlayered with a 40% to 20% continuous sucrose gradient (B). Fractions were analyzed for TF activity (A and B), protein (A), or density (B) using a refractometer. Active TF has been found in whole blood and plasma. [17] [18] [19] [20] Recent data suggest that circulating TF may serve as more than a marker for TF produced at sites of vascular injury and that it may play a primary role in the initiation or propagation of arterial thrombosis. 19 The sources of extracellular and plasma TF remain to be determined, as do the structures in which they are contained. Some of the plasma TF may derive from vesicles in the arterial wall that are exposed by injury and dislodged into the circulation. We have recently measured TF activity on the surface of injured rat aorta in a flow chamber. 16 A surprising finding was that all measurable TF activity on the luminal surface was released into the perfusate, suggesting that active intimal TF might be rapidly washed away by circulating blood. This clearance of active TF might be important in preventing occlusive thrombosis at sites of arterial injury while simultaneously rendering circulating blood more thrombogenic. The present study provides a potential source for the extracellular TF activity found in the arterial wall. We hypothesize that active intimal TF derives mainly from the release of TF-containing vesicles from the surface of activated SMCs. This provides a reservoir of active TF that persists even after intimal SMCs return to a quiescent state. A similar mechanism involving macrophages and SMCs may account for a substantial portion of the extracellular TF seen in atherosclerotic plaques. Immunoprecipitation of TF activity. SMCs were incubated for 24 hours in DM with or without 10 ng/mL PDGF. The medium was concentrated and aliquots were immunoprecipitated with antibodies conjugated to protein A sepharose beads. A, TF activity remaining in the supernatant after precipitation relative to the activity originally measured in the medium. B, TF activity in the immunoprecipitate relative to activity originally measured in the medium. Experiments were done in duplicate on duplicate samples. *PϽ0.005 compared with medium alone; †PϽ0.001 compared with medium alone; and #PϽ0.005 compared with beads.
Expression of Surface Antigens on SMCs and Microparticles
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